Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
Science Translational Medicine.
Times cited: 568
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.
Times cited: 536
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997).
Times cited: 101